AI assistant
SUPERNUS PHARMACEUTICALS, INC. — Director's Dealing 2012
Apr 30, 2012
31512_dirs_2012-04-30_0d9f226e-12d6-4994-b76f-eb8db4162c30.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: SUPERNUS PHARMACEUTICALS INC (SUPN)
CIK: 0001356576
Period of Report: 2012-04-30
Reporting Person: BARRETT M JAMES (Director, 10% Owner)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A Preferred Stock | $ | Common Stock (6241250) | Indirect |
Footnotes
F1: The shares of Series A Preferred Stock (the "Shares") will convert automatically into the number of shares of Common Stock set forth above, without the payment of any additional consideration upon the closing of the Issuer's initial public offering. The Shares do not have an expiration date.
F2: The Reporting Person is a manager of NEA 11 GP, LLC, which is the sole general partner of NEA Partners 11, Limited Partnership ("NEA Partners 11"). NEA Partners 11 is the sole general partner of New Enterprise Associates 11, Limited Partnership ("NEA 11"), the direct beneficial owner of the Shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of the Shares held by NEA 11, except to the extent of his pecuniary interest therein.